We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Releases Encouraging Evalut TAVR Result
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) recently presented the initial clinical outcome of its Evolut Low Risk Trial at the 68th Annual Scientific Session of the American College of Cardiology. This data was also published in the New England Journal of Medicine.
The clinical program was aimed at comparing the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in younger, healthier aortic stenosis patients.
Per Medtronic, these low-risk aortic stenosis patients have special characteristics on account of their tendency to be younger and active as compared to their higher-risk counterparts. The study itself is significant and timely considering the fact that there are 165,000 low-risk patients suffering severe aortic stenosis per year in the United States, Western Europe and Japan. If left untreated, the ailment can cause heart failure within a span of two years.
Data at a Glance
In the second year, the findings of this randomized Evolut Low Risk study claim to meet its primary non-inferiority endpoint of all-cause mortality or disabling stroke as compared to surgery. More specifically, all-cause mortality or disabling stroke incident was 5.3% with the Evolut TAVR as compared to 6.7% incident with traditional surgery.
This apart, the pre-specified 30-day safety composite of all-cause mortality, disabling stroke, life-threatening bleeding, major vascular complications or acute kidney injury was significantly lower for TAVR in comparison to open heart surgery.
Peer Threat
Medtronic’s success from this favorable study outcome has too some extent disappeared following its rival in this field — Edwards’ Lifesciences (EW - Free Report) — releasing a Phase 3 clinical trial outcome of its PARTNER 3 study on SAPIEN 3 mitral valve in patients with severe symptomatic aortic stenosis. Edwards’ data showed a 1% incident for all-cause mortality or disabling stroke in these patients.
Other major peers of Medtronic in this field are Boston Scientific Corporation (BSX - Free Report) and Abbott Laboratories (ABT - Free Report) who are also presenting their study results at the latest session of the Americal College of Cardiology.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Medtronic (MDT) Releases Encouraging Evalut TAVR Result
Medtronic plc (MDT - Free Report) recently presented the initial clinical outcome of its Evolut Low Risk Trial at the 68th Annual Scientific Session of the American College of Cardiology. This data was also published in the New England Journal of Medicine.
The clinical program was aimed at comparing the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in younger, healthier aortic stenosis patients.
Per Medtronic, these low-risk aortic stenosis patients have special characteristics on account of their tendency to be younger and active as compared to their higher-risk counterparts. The study itself is significant and timely considering the fact that there are 165,000 low-risk patients suffering severe aortic stenosis per year in the United States, Western Europe and Japan. If left untreated, the ailment can cause heart failure within a span of two years.
Data at a Glance
In the second year, the findings of this randomized Evolut Low Risk study claim to meet its primary non-inferiority endpoint of all-cause mortality or disabling stroke as compared to surgery. More specifically, all-cause mortality or disabling stroke incident was 5.3% with the Evolut TAVR as compared to 6.7% incident with traditional surgery.
This apart, the pre-specified 30-day safety composite of all-cause mortality, disabling stroke, life-threatening bleeding, major vascular complications or acute kidney injury was significantly lower for TAVR in comparison to open heart surgery.
Peer Threat
Medtronic’s success from this favorable study outcome has too some extent disappeared following its rival in this field — Edwards’ Lifesciences (EW - Free Report) — releasing a Phase 3 clinical trial outcome of its PARTNER 3 study on SAPIEN 3 mitral valve in patients with severe symptomatic aortic stenosis. Edwards’ data showed a 1% incident for all-cause mortality or disabling stroke in these patients.
Other major peers of Medtronic in this field are Boston Scientific Corporation (BSX - Free Report) and Abbott Laboratories (ABT - Free Report) who are also presenting their study results at the latest session of the Americal College of Cardiology.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>